Queerty is better as a member
This isn’t news … The news from the conference is Sangamo’s “Functional Cure” for HIV/AIDS which is getting virtually no coverage.
Tiny Sangamo BioSciences Inc.’s potential “functional cure” for HIV is getting big attention in advance of a major AIDS scientific meeting.
SB-728-T, a gene therapy designed to knock out the CCR5 receptor on CD4 cells, protects and increases CD4s in patients experiencing poor immunologic recovery while on antiretroviral (ARV) therapy, according to preliminary Phase I study data reported on Monday, February 28, at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. The new results, reported by Jay Lalezari, MD, are among the first from a human study illustrating the therapeutic—and curative—potential of this novel approach being developed by Sangamo BioSciences.
Please log in to add your comment.
Need an account? Register It's free and easy.
PHOTOS: Gay Cowboys Lasso The American West
PHOTOS: Idina Menzel Back on Broadway in If/Then
PHOTOS: A Glittering Night Of Body Painting, Hookah Circus & Porn Stars
PHOTOS: New York City Prepares For The Black Party Weekend
Photos: Take A Glimpse Inside The Lives Of Soldiers, Boys And Biblical Figures